Cutera INC 8-K filings

Cutera, Inc. has formally notified Nasdaq of its intention to voluntarily delist its common stock following the commencement of Chapter 11 proceedings.

Cutera, Inc. received notification from Nasdaq regarding the delisting of its common stock due to the company's commencement of voluntary Chapter 11 proceedings.

Cutera, Inc. has filed for Chapter 11 bankruptcy protection to implement a pre-packaged financial restructuring plan, aiming to reduce debt by nearly $400 million and raise $65 million in new funding.

Jeryl Hilleman resigns from Cutera's board, and Paul Wierbicki is appointed as her replacement with a special compensation agreement.

Cutera's executive officers will receive special cash performance and incentive bonuses, subject to repayment conditions based on their departure date.

Cutera Inc. has been notified by Nasdaq that it does not meet the minimum market value of publicly held shares requirement for continued listing.

Cutera's third-quarter results show a significant revenue decrease year-over-year, though the company maintains its full-year guidance and sees growth in its AviClear product line.

Cutera Inc. received a Nasdaq deficiency notice for its stock price falling below $1.00 and announced the resignation of its Chief Technology Officer.

Cutera's second quarter revenue declined 44% year-over-year, prompting revised full-year guidance and additional cost-cutting measures.

Cutera, Inc. successfully held its 2024 Annual Meeting of Stockholders, where all director nominees were elected and key proposals were approved, including an amendment to the 2019 Equity Incentive Plan.

Cutera, Inc. announced the resignation of Sheila A. Hopkins from its board of directors and the appointment of Jeryl (Jeri) Hilleman, effective July 12, 2024.

Cutera, Inc. has reached a settlement agreement with Lutronic Aesthetics, Inc., resolving all outstanding litigation and arbitration matters, with Lutronic agreeing to pay Cutera $5.75 million.

Cutera has amended its previously released financial results for 2023 due to significant adjustments, primarily related to inventory reserves and manufacturing agreement termination costs.

Cutera's first quarter 2024 results show a significant revenue decrease of 29% year-over-year, though the company highlights strong growth in AviClear revenue and improved gross margins.

Cutera, Inc. has terminated its $30 million revolving credit facility with First-Citizens Bank, which was never utilized.

Cutera's Q4 2023 revenue was $49.5 million, a 26% decrease year-over-year, while full-year revenue reached $212.4 million, exceeding prior guidance.

Cutera Inc. has revised its non-GAAP financial measures for the second quarter of 2023 to reflect a restatement of previously issued financial statements due to material errors in accounting for physical inventory.

Cutera has revised its first quarter 2023 non-GAAP financial measures to correct errors related to inventory accounting and internal control deficiencies.

Cutera has restated its financial statements for Q1 and Q2 2023 due to inventory errors, released its Q3 2023 results, and is working to regain compliance with Nasdaq listing rules.

Cutera has reached a $19.5 million settlement with Jabil over a manufacturing agreement termination and ended its distribution agreement with ZO Skin Health in Japan for $11.5 million.